Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 2
2020 1
2021 5
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
CONCLUSIONS: Prasinezumab therapy had no meaningful effect on global or imaging measures of Parkinson's disease progression as compared with placebo and was associated with infusion reactions. (Funded by F. Hoffmann-La Roche and Prothena Biosciences; PASADENA ClinicalTrial …
CONCLUSIONS: Prasinezumab therapy had no meaningful effect on global or imaging measures of Parkinson's disease progression as compared with …
Final Report of a Trial of Intensive versus Standard Blood-Pressure Control.
SPRINT Research Group; Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, Evans GW, Johnson KC, Kitzman DW, Oparil S, Rahman M, Reboussin DM, Rocco MV, Sink KM, Snyder JK, Whelton PK, Williamson JD, Wright JT Jr, Ambrosius WT. SPRINT Research Group, et al. N Engl J Med. 2021 May 20;384(20):1921-1930. doi: 10.1056/NEJMoa1901281. N Engl J Med. 2021. PMID: 34010531 Free PMC article. Clinical Trial.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
Key inclusion criteria were: aged 40-80 years; Hoehn & Yahr (H&Y) Stage I or II; time from diagnosis 2 years; having bradykinesia plus one other cardinal sign of PD (e.g., resting tremor, rigidity); DAT-SPECT imaging consistent with PD; and either treatment naive o …
Key inclusion criteria were: aged 40-80 years; Hoehn & Yahr (H&Y) Stage I or II; time from diagnosis 2 years; having bradykinesia pl …
European Space Agency experiments on thermodiffusion of fluid mixtures in space.
Braibanti M, Artola P-, Baaske P, Bataller H, Bazile J-, Bou-Ali MM, Cannell DS, Carpineti M, Cerbino R, Croccolo F, Diaz J, Donev A, Errarte A, Ezquerro JM, Frutos-Pastor A, Galand Q, Galliero G, Gaponenko Y, García-Fernández L, Gavaldá J, Giavazzi F, Giglio M, Giraudet C, Hoang H, Kufner E, Köhler W, Lapeira E, Laverón-Simavilla A, Legros J-, Lizarraga I, Lyubimova T, Mazzoni S, Melville N, Mialdun A, Minster O, Montel F, Molster FJ, Ortiz de Zárate JM, Rodríguez J, Rousseau B, Ruiz X, Ryzhkov II, Schraml M, Shevtsova V, Takacs CJ, Triller T, Van Vaerenbergh S, Vailati A, Verga A, Vermorel R, Vesovic V, Yasnou V, Xu S, Zapf D, Zhang K. Braibanti M, et al. Eur Phys J E Soft Matter. 2019 Jul 11;42(7):86. doi: 10.1140/epje/i2019-11849-0. Eur Phys J E Soft Matter. 2019. PMID: 31289962 Free article. Review.
Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study.
Naismith RT, Bermel RA, Coffey CS, Goodman AD, Fedler J, Kearney M, Klawiter EC, Nakamura K, Narayanan S, Goebel C, Yankey J, Klingner E, Fox RJ; SPRINT-MS investigators. Naismith RT, et al. Neurology. 2021 Jan 26;96(4):e491-e500. doi: 10.1212/WNL.0000000000011314. Epub 2020 Dec 2. Neurology. 2021. PMID: 33268562 Free PMC article. Clinical Trial.
Effect of preshipment preconditioning and injectable antioxidant trace elements (Cu, Mn, Se, Zn) and vitamins (A, E) on plasma metabolite and hormone concentrations and growth in weaned beef cattle.
Galarza EM, Lizarraga RM, Mattioli GA, Parker AJ, Relling AE. Galarza EM, et al. Transl Anim Sci. 2021 Jan 4;5(1):txaa233. doi: 10.1093/tas/txaa233. eCollection 2021 Jan. Transl Anim Sci. 2021. PMID: 33542997 Free PMC article.
The experiment used a 2 2 factorial arrangement design, considering a 26-d PC treatment from weaning to transport to the feedlot (day 0), and injectable MVS on days -45, -26, and 0. The MVS consisted of Cu, Zn, Mn, Se, vitamin E (0.2, 0.8, 0.2, 0.1, and 1 mg/kg body weight …
The experiment used a 2 2 factorial arrangement design, considering a 26-d PC treatment from weaning to transport to the feedlot (day 0), an …
Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes.
Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, Gure TR, Kimmel PL, Kirchner K, Morisky DE, Newman J, Olney C, Oparil S, Pajewski NM, Powell J, Ramsey T, Simmons DL, Snyder J, Supiano MA, Weiner DE, Whittle J; SPRINT Research Group. Berlowitz DR, et al. N Engl J Med. 2017 Aug 24;377(8):733-744. doi: 10.1056/NEJMoa1611179. N Engl J Med. 2017. PMID: 28834483 Free PMC article. Clinical Trial.
Effect of age, ethnicity, sex, cognitive status and APOE genotype on amyloid load and the threshold for amyloid positivity.
Duara R, Loewenstein DA, Lizarraga G, Adjouadi M, Barker WW, Greig-Custo MT, Rosselli M, Penate A, Shea YF, Behar R, Ollarves A, Robayo C, Hanson K, Marsiske M, Burke S, Ertekin-Taner N, Vaillancourt D, De Santi S, Golde T, St D. Duara R, et al. Neuroimage Clin. 2019;22:101800. doi: 10.1016/j.nicl.2019.101800. Epub 2019 Mar 27. Neuroimage Clin. 2019. PMID: 30991618 Free PMC article.
We calculated quantitative amyloid load, measured as Standardized Uptake Value Ratios (SUVRs) using [18-F]florbetaben PET scans, for 159 Hispanic and non-Hispanic participants, who had been classified clinically as Cognitively Normal (CN), Mild Cognitive Impairment (MCI) o …
We calculated quantitative amyloid load, measured as Standardized Uptake Value Ratios (SUVRs) using [18-F]florbetaben PET scans, for …
Application of Quality by Design to the robust preparation of a liposomal GLA formulation by DELOS-susp method.
Merlo-Mas J, Tomsen-Melero J, Corchero JL, González-Mira E, Font A, Pedersen JN, García-Aranda N, Cristóbal-Lecina E, Alcaina-Hernando M, Mendoza R, Garcia-Fruitós E, Lizarraga T, Resch S, Schimpel C, Falk A, Pulido D, Royo M, Schwartz S Jr, Abasolo I, Pedersen JS, Danino D, Soldevila A, Veciana J, Sala S, Ventosa N, Córdoba A. Merlo-Mas J, et al. J Supercrit Fluids. 2021 Jul;173:105204. doi: 10.1016/j.supflu.2021.105204. J Supercrit Fluids. 2021. PMID: 34219919 Free PMC article.